🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Biogen Stock Is Surging Today: What's Going On?

Published 30/11/2022, 14:16
© Reuters.  Biogen Stock Is Surging Today: What's Going On?
BIIB
-
BIIB34
-

Benzinga - Biogen Inc (NASDAQ: NASDAQ:BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's drug lecanemab.

Biogen presented the results from a large global Phase 3 confirmatory Clarity Alzheimer's disease clinical study of lecanemab at the 2022 Clinical Trials on Alzheimer's Disease conference.

The primary endpoint was change from baseline at 18 months in the global cognitive and functional scale. Biogen said lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale, compared with placebo at 18 months by -0.45, representing a 27% slowing of decline.

The company said all key secondary endpoints also showed highly statistically significant results compared with placebo.

Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological diseases. Lecanemab is an investigational humanized monoclonal antibody for Alzheimer's. It's being developed jointly with Eisai.

BIIB Price Action: Biogen has a 52-week high of $307.53 and a 52-week low of $187.16.

The stock was up 5.01% at $306 at time of publication, according to Benzinga Pro.

Photo: fernando zhiminaicela from Pixabay.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.